For personal use only

ASX ANNOUNCEMENT
22 July 2026

PainChek receives $1.123 million R&D tax incentive refund

- **$1.123 million R&D tax incentive refund received, strengthening PainChek's cash position and supporting continued investment in product development and commercialisation.**
- **Refund relates to eligible FY2025 expenditure, including development of the PainChek Adult and Infant algorithms and validation activities supporting US market entry and the use of PainChek's technology in children.**

Sydney, Australia, 22 July 2026: PainChek Ltd (ASX: PCK), developer of the world's first AI-powered pain assessment and monitoring application, is pleased to announce that the Company has received a $1.123 million research and development (R&D) tax incentive refund for the 2025 financial year.

The refund relates to R&D undertaken in support of PainChek's core focus on advancing and commercialising its AI-enabled pain assessment platform. The eligible work included continued development of the PainChek Adult and Infant algorithms, together with validation activities supporting the Company's entry into the US market and the expansion of its technology for use in children.

The R&D Tax Incentive is an Australian Government program that supports companies undertaking eligible R&D activities in Australia. Under the program, eligible companies may receive a cash offset of up to 43.5% of qualifying R&D expenditure.

This announcement has been approved for release by the Board.

For more information:

Natalie Climo
Company Secretary, PainChek
natalie.climo@boardroomlimited.com.au
02 8016 2875

For personal use only

About PainChek

PainChek® is the world's first regulatory-cleared medical device for the assessment of pain, enabling best-practice pain management for people living with pain in any environment, from those who cannot reliably self-report their pain, those who can, and for those whose ability to self-report their pain fluctuates.

Globally, PainChek® has attained regulatory clearance as a medical device in Australia, Canada, the European Union, New Zealand, Singapore, Malaysia, the United Kingdom and most recently FDA De Novo clearance in the United States.

PainChek® has contracts with over 2,000 aged care facilities, with more than 20,000,000 digital pain assessments conducted to date, and is trusted by thousands of nurses, carers, and clinicians.

PainChek® is setting a new benchmark for pain assessment. Being the first TGA-approved and FDA-cleared medical device for pain assessment, PainChek® combines AI and Human Intelligence to detect pain in people who cannot reliably self-report.

For more information, visit: https://painchek.com